PHAS has seen it's short interest growing, 1.75 million on Nov 15 up to 1.93 end of Nov. In June short interest was around 500,000. Seems to be one of their playgrounds.
Recent, meaning yesterday's bounce prolly some short cover. Then bang it down again today.
The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor.
The way I understand it, there is currently no reversal for the blood thinner, ticagrelor. Other than the time necessary for the body to replace it by the making of new blood cells.